TELIX Pharmaceuticals Ltd (TLX) — Capital Reinvestment Ratio
Latest as of June 2025:
0.36x
TELIX Pharmaceuticals Ltd (TLX) has a Capital Reinvestment Ratio of 0.36x as of June 2025, meaning it reinvests 0% of its operating cash flow (AU$27.98 Million) in capital expenditures (AU$10.13 Million). See TLX free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.36x
Capex / Operating Cash Flow
Operating Cash Flow
AU$27.98 Million
AUD
Capital Expenditures
AU$10.13 Million
AUD
Data as of
Jun 2025
Most recent filing
TELIX Pharmaceuticals Ltd Capital Reinvestment Ratio (2020–2024)
This chart tracks TELIX Pharmaceuticals Ltd's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for TELIX Pharmaceuticals Ltd (2020–2024)
Year-by-year Capital Reinvestment Ratio for TELIX Pharmaceuticals Ltd from 2020 to 2024. For live market cap and broader valuation context, see TELIX Pharmaceuticals Ltd market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (AUD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.79x | AU$43.03 Million | AU$34.03 Million | ▲ +75.0% |
| 2023 | 0.45x | AU$23.88 Million | AU$10.79 Million | ▲ +175.1% |
| 2020 | 0.16x | AU$1.96 Million | AU$322.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow